Abbott stock fell victim to an old earnings season truth: It's all about the guidance
-
最新报道：Abbott Laboratories' stock dropped sharply after its Q2 earnings report, despite beating revenue and profit estimates. The healthcare giant reported $10.2 billion in sales and $1.17 EPS, surpassing Wall Street's expectations. However, investors focused on the company's lowered full-year guidance, now projecting $4.30-$4.50 EPS compared to previous $4.50-$4.70 range. CEO Robert Ford cited weaker-than-expected COVID testing demand and foreign exchange headwinds as primary reasons for the guidance cut. The stock fell 8% in premarket trading, marking its worst single-day decline since 2020. Analysts noted this reaction highlights how markets prioritize future outlooks over past performance during earnings season.
下一篇
The GENIUS Act could be Ethereum’s next catalyst – Here’s how
- The "Genius Act" proposed by U.S. lawmakers could serve as a major catalyst for Ethereum b...
24小时热点
热点专题
407106